View in EDS

Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma.

Saved in:
Bibliographic Details
Title: Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma.
Authors: Calaud C; Centre Méditerranéen de Médecine Moléculaire U1065, Université Côte d'Azur, INSERM, Nice, France.; Equipe Leader Fondation ARC 2023, Nice, France., Serrano-Lopez EM; Centre Méditerranéen de Médecine Moléculaire U1065, Université Côte d'Azur, INSERM, Nice, France.; Equipe Leader Fondation ARC 2023, Nice, France., Cluse LA; Cancer Biology and Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia., Todorovski I; Cancer Biology and Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia., Mardivirin T; Centre Méditerranéen de Médecine Moléculaire U1065, Université Côte d'Azur, INSERM, Nice, France.; Equipe Leader Fondation ARC 2023, Nice, France., Teater MR; Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY., Maarad A; Centre Méditerranéen de Médecine Moléculaire U1065, Université Côte d'Azur, INSERM, Nice, France.; Equipe Leader Fondation ARC 2023, Nice, France., Tawfic N; Cancer Biology and Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia., Fraser PJ; Cancer Biology and Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia., Guiraud K; Centre Méditerranéen de Médecine Moléculaire U1065, Université Côte d'Azur, INSERM, Nice, France.; Equipe Leader Fondation ARC 2023, Nice, France., Dupont C; Centre Méditerranéen de Médecine Moléculaire U1065, Université Côte d'Azur, INSERM, Nice, France.; Equipe Leader Fondation ARC 2023, Nice, France., Menigot C; Centre Méditerranéen de Médecine Moléculaire U1065, Université Côte d'Azur, INSERM, Nice, France.; Equipe Leader Fondation ARC 2023, Nice, France., Sant'Anna-Silva ACB; Centre Méditerranéen de Médecine Moléculaire U1065, Université Côte d'Azur, INSERM, Nice, France., Yoannidis D; Molecular Genomics Core, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Semple T; Molecular Genomics Core, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Kerreneur E; Centre Méditerranéen de Médecine Moléculaire U1065, Université Côte d'Azur, INSERM, Nice, France., Rocchi S; Centre Méditerranéen de Médecine Moléculaire U1065, Université Côte d'Azur, INSERM, Nice, France., Jacquel A; Centre Méditerranéen de Médecine Moléculaire U1065, Université Côte d'Azur, INSERM, Nice, France., Melnick AM; Institut de Recerca contra la Leucèmia Josep Carreras, Badalona, Barcelona, Spain., Johnstone RW; Cancer Biology and Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia., Dominguez PM; Centre Méditerranéen de Médecine Moléculaire U1065, Université Côte d'Azur, INSERM, Nice, France.; Equipe Leader Fondation ARC 2023, Nice, France.
Source: Blood neoplasia [Blood Neoplasia] 2026 Mar 02; Vol. 3 (2), pp. 100214. Date of Electronic Publication: 2026 Mar 02 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 9918841988906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2950-3280 (Electronic) Linking ISSN: 29503280 NLM ISO Abbreviation: Blood Neoplasia Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2950-3280
DOI:10.1016/j.bneo.2026.100214